Zoetis (NYSE:ZTS) Stock, Quote.Headers.trade-ideas

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Jim Cramer

News

Media

Jim Cramer Recommends Not Buying Mosaic, Doesn&#39;t Like This Industrial Stock

Investors,Analyze,Graph,Data,Stock,Market,Index,Via,Digital,Tablet

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Large Cap

Macro Economic Events

Mid Cap

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Small Cap

Global

Econ #s

Economics

ETFs

$BTC

ANET

BALL

COTY

CPAY

CTRA

SPDR Dow Jones Industrial Average ETF Trust

EXPD

FANG

JKHY

LDOS

LSCC

PLTR

RIVN

SMCI

VRTX

WYNN

Select Sector SPDR-Consumer Discretionary

Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.

Stocks Fall On Trade Concerns, Oil And Gold Rally: What&#39;s Driving Markets Tuesday?

Earnings

Guidance

Health Care

General

Zoetis beats Q1 estimates with $1.48 EPS and $2.22 billion revenue, raises full-year forecast on strong demand for companion animal health products.

Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact

Zoetis Inc

Ztest Electronics Inc

Press Releases

Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?

Zoetis Announces U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain

Zoetis Declares Second Quarter 2025 Dividend

Zoetis Reports Fourth Quarter and Full Year 2024 Results

Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus

Zoetis to Participate in Upcoming Investor Conferences

Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

Zoetis Announces First Quarter 2025 Results

Zoetis Declares Third Quarter 2025 Dividend

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Zoetis

Zoetis (NYSE:ZTS) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell